Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PYC TherapeuticsASX:PYC -0.90%31 EV-to-EBITDA is -32.09 as of Jul. 24, 2026. GuruFocus rates ASX:PYC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 402 Biotechnology companies, PYC Therapeutics ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PYC Therapeutics's enterprise value is A$1,527.66 Mil.
PYC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-47.60 Mil. Therefore, PYC Therapeutics's EV-to-EBITDA for today is -32.09.
The historical rank and industry rank for PYC Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:PYC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.83 Med: -31.98 Max: -3.14
Current: -32.09
During the past 13 years, the highest EV-to-EBITDA of PYC Therapeutics was -3.14. The lowest was -93.83. And the median was -31.98.
ASX:PYC's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs ASX:PYC: -32.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PYC Therapeutics's PE Ratio (TTM) for today is calculated as:
PYC Therapeutics's share price for today is A$1.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.083.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PYC Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PYC vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, PYC Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PYC Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PYC Therapeutics's EV-to-EBITDA falls into.
PYC Therapeutics's current Enterprise Value is A$1,527.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-47.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYC Therapeutics (ASX:PYC) has a EV-to-EBITDA of -32.09 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PYC Therapeutics. According to the industry distribution chart, PYC Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry.
Is PYC Therapeutics' EV-to-EBITDA too high?
PYC Therapeutics' current EV-to-EBITDA is -32.09. Based on the distribution chart, PYC Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PYC Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #999999 out of 402 companies for EV-to-EBITDA. This places PYC Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PYC Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PYC Therapeutics's current EV-to-EBITDA is -32.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current EV-to-EBITDA of -32.09. The current EV-to-EBITDA is -32.09. PYC Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current EV-to-EBITDA is -32.09 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
31GF Score
Get the complete analysis for ASX:PYC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PYC has been successfully added to your 
